Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CIALIS

« Back to Dashboard

Summary for Tradename: CIALIS

Patents:5
Applicants:1
NDAs:1
Suppliers: see list9
2013 Sales:$1,086,355,000

Pharmacology for Tradename: CIALIS

Clinical Trials for: CIALIS

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status: Active, not recruiting Condition: Pulmonary Arterial Hypertension; Systemic Sclerosis; Scleroderma Spectrum of Diseases; Connective Tissue Disease; Pulmonary Hypertension

Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying
Status: Completed Condition: Gastroparesis

A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
Status: Completed Condition: Erectile Dysfunction

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
Status: Completed Condition: Benign Prostatic Hyperplasia

A Study of Tadalafil in Benign Prostatic Hyperplasia
Status: Completed Condition: Benign Prostatic Hyperplasia

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction
Status: Completed Condition: Erectile Dysfunction

A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
Status: Completed Condition: Erectile Dysfunction

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Status: Completed Condition: Hypertension, Pulmonary

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Completed Condition: Benign Prostatic Hyperplasia

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
Status: Completed Condition: Pulmonary Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
CIALIS
tadalafil
TABLET;ORAL021368Nov 21, 2003RXYes5,859,006<disabled>YY<disabled>
Lilly
CIALIS
tadalafil
TABLET;ORAL021368Jan 7, 2008RXNo6,140,329<disabled>Y<disabled>
Lilly
CIALIS
tadalafil
TABLET;ORAL021368Nov 21, 2003RXNo<disabled><disabled>
Lilly
CIALIS
tadalafil
TABLET;ORAL021368Nov 21, 2003RXYes6,140,329<disabled>Y<disabled>
Lilly
CIALIS
tadalafil
TABLET;ORAL021368Jan 7, 2008RXNo6,943,166<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CIALIS

Drugname Dosage Strength RLD Submissiondate
tadalafilTablets2.5 mgCialis10/14/2008
tadalafilTablets5 mg, 10 mg and 20 mgCialis11/21/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc